ReviewWorld journal of gastroenterology2014
Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Long-term outcomes of patients with hepatitis C virus-related liver transplantation in a high-volume transplant center.BMC gastroenterology · 2026Article
- Molecular mechanisms implicated in SARS-CoV-2 liver tropism.World journal of gastroenterology · 2022Review
- Liver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- Revolution in the diagnosis and management of hepatitis C virus infection in current era.World journal of hepatology · 2022Article
- Outcome of hepatitis C-related liver transplantation in direct-acting antiviral era.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Article
- Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma.Digestive diseases and sciences · 2019Review
- Retrospective Cohort Study: Ledipasvir-Sofosbuvir With/Without Ribavirin for Chronic Hepatitis C Post-Liver Transplant in a Real-World Population.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2018Article
- Efficacy And Safety of Sofosbuvir Based Regimens For Treatment of Hepatitis C Recurrence After Living Donor Liver Transplantation: An Experience From India.Journal of clinical and experimental hepatology · 2018Article
- Change in Health Insurance Coverage After Liver Transplantation Can Be Associated with Worse Outcomes.Digestive diseases and sciences · 2018Article
- Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.World journal of gastroenterology · 2015Article
- Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2015Article
- Treatment of hepatocellular carcinoma: Steps forward but still a long way to go.World journal of hepatology · 2015Review
- Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir.International journal of organ transplantation medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV)-related liver disease, including cirrhosis and hepatocellular carcinoma is the main indication for liver transplantation (LT) worldwide. Post-transplant HCV re-infection is almost universal and results in accelerated progression from acute hepatitis to chronic hepatitis, and liver cirrhosis. Comprehension and treatment of recurrent HCV infection after LT have been major issues for all transplant hepatologists and transplant surgeons for the last decades. The aim of this paper is to review the evolution of our knowledge on the natural history of HCV recurrence after LT, including risk factors for disease progression, and antiviral therapy. We will focus our attention on possible ways (present and future) to improve the final long-term results of LT for HCV-related liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.